外阴恶性肿瘤腹股沟淋巴结转移与预后的关系

目的 探讨腹股沟及盆腔淋巴结转移情况及其对预后的影响。方法 对36％例行腹股沟淋巴结清除术的外阴恶性肿瘤患者进行回顾性分析。结果 腹股沟淋巴结阳性者13例,阳性率36.1％(13/36),5年生存率为15.4％(2/13);腹股沟淋巴结阴性者5年生存率为91.7％(11/12),并且随局部病灶的增大,腹股沟淋巴结转移率明显升高。结论 局部病灶大小及肿瘤病理类型与腹股沟淋巴结转移密切相关,成为影响外阴恶性肿瘤预后的主要因素。     

早期宫颈癌淋巴脉管间隙浸润与临床病理因素及预后的关系

目的:研究早期宫颈癌淋巴脉管间隙浸润(LVSI)与临床病理因素及预后的关系,以指导早期宫颈癌的治疗并判断预后。方法:回顾性收集280例早期宫颈癌(ⅠA2~ⅡB)患者的临床及病理资料,所有患者2009年1月至2012年6月于大连市妇产医院初治手术治疗,术式为经腹或腹腔镜下广泛性子宫切除术+盆腔淋巴结切除术±腹主动脉旁淋巴结切除术。根据术后是否存在高危因素,进行辅助放疗或联合放化疗。采用单因素分析研究LVSI与各临床病理因素的关系,进一步对单因素分析结果中与LVSI关系显著的临床病理因素进行多因素分析,确定其独立的危险因素。绘制生存曲线,确定LVSI对患者生存的影响。结果:①单因素分析显示:LVSI与宫颈癌组织学类型、分化程度、淋巴结转移、浸润深度有关(P<0.05),与年龄、宫旁受累、病灶大小、FIGO分期无关(P>0.05);多因素分析显示LVSI是分化程度、淋巴结转移及浸润深度的独立危险因素(P<0.05)。②LVSI阳性患者的5年无病生存率为74%,总生存率为80%;LVSI阴性患者的5年无病生存率及总生存率均为93%(P<0.05)。结论:LVSI阳性一定程度上能更早地提示淋巴结转移的潜在风险,是发生淋巴结转移的独立危险因素,并能显著降低早期宫颈癌患者的5年无病生存率及总生存率。LVSI阳性早期宫颈癌患者可能浸润深度更深、分化程度更差,但需更多研究证实。     

宫颈癌根治术中加行腹主动脉旁淋巴结切除在ⅠB2及ⅡA2期宫颈癌治疗中的临床价值

目的:探讨宫颈癌根治术中加行腹主动脉旁淋巴结切除在Ⅰ B2及ⅡA2期宫颈癌治疗中的临床应用价值.方法:选择2006年5月至2011年7月在我院诊治的Ⅰ B2及ⅡA2期宫颈癌患者86例,分成两组.对照组45例,行宫颈癌根治术;观察组41例,宫颈癌根治术中加行腹主动脉旁淋巴结切除术;两组术后辅以放疗或放化疗.对两组术中、术后情况及复发率、生存率进行比较分析,并分析盆腔淋巴结转移、腹主动脉旁淋巴结转移与临床病理因素的关系.结果:观察组复发6例,复发率为15.0％;48个月总生存率和无瘤生存率均为70.0％.对照组复发17例,复发率为38.6％;48个月总生存率和无瘤生存率分别为68.0％和66.0％.两组比较,差异均有统计学意义(P＜0.05).两组并发症发生率(29.3vs 40.0％)、术中出血量(325.0±58.0ml vs 315.0±50.1 ml)及盆腔淋巴结阳性率(56.1％vs 57.8％)比较,差异均无统计学意义(P＞0.05).观察组中腹主动脉旁淋巴结阳性率为17.1％,盆腔淋巴结转移个数与腹主动脉旁淋巴结转移呈正相关(P＜0.01).单因素分析表明腹主动脉旁淋巴结转移是影响宫颈癌患者预后的因素之一(P＜0.05);多因素分析则表明盆腔淋巴结转移个数及腹主动脉旁淋巴结转移是影响宫颈癌患者预后的因素之一(P＜0.05).结论:宫颈癌盆腔淋巴结转移个数与腹主动脉旁淋巴结转移有关.在宫颈癌根治性手术中加腹主动脉旁淋巴结切除并辅以术后治疗,可以降低复发率,提高生存率,且安全可行.     

外阴癌82例预后相关因素分析

目的探讨外阴癌的临床病理因素及治疗方式对预后的影响。方法收集辽宁省肿瘤医院2004年1月至2010年6月收治的82例原发外阴癌患者的临床病例资料,对预后影响因素进行回顾性分析。结果 82例外阴癌患者中,中位年龄为55岁(29~82岁)。总的5年生存率为72%。按2009年FIGO手术病理分期,Ⅰ期40例,Ⅱ期5例,Ⅲ期24例,Ⅳ期4例,未能进行手术病理分期者9例。其中Ⅰ~Ⅱ期及Ⅲ~Ⅳ期5年生存率分别为86%、61%,两组生存率差异有统计学意义(P0.05)。鳞癌68例,非鳞癌14例,5年生存率分别为73%、79%(P0.05)。有病理分级报告的68例患者中G1组62例,G2~G3组6例,5年生存率分别为93%、71%(P0.05)。79例行手术治疗,其中72例行外阴广泛性切除术及双侧腹股沟浅淋巴结切除术,术后病理无淋巴结转移48例,有淋巴结转移24例,5年生存率分别为80%、58%,两组之间生存率差异有统计学意义(P0.05)。单纯手术组46例,手术加辅助治疗组33例,根治性放化疗组3例,5年生存率分别为72%、77%、60%,3组间差异无统计学意义(P0.05)。结论外阴癌的5年生存率较高,临床分期、腹股沟淋巴结转移是影响外阴癌预后的不良因素。     

435例子宫内膜癌综合治疗疗效分析

目的探讨子宫内膜癌患者综合治疗后的生存情况。方法回顾性分析1992年1月至2009年12月收治的有完整随访资料的435例子宫内膜癌患者的临床病理资料,分析不同治疗方案对患者预后的影响。结果 435例患者的中位随访时间为55.5个月,其中59例(13.6%)患者复发,58例(13.3%)患者死亡,5年总生存率为92.2%,5年无瘤生存率为88.3%。术后单纯辅助孕激素治疗≥12个月者5年无瘤生存率[(95.1±2.7)%]显著高于术后无辅助治疗组[(93.1±2.7)%,P<0.05];术后孕激素+放疗组患者5年总生存率[(94.3±6.5)%]、5年无瘤生存率[(86.1±10.8)%]均显著高于术后单纯放疗组[均为(69.4±14.4)%,P<0.05)];术后单纯化疗组5年总生存率[(84.2±6.3)%]、5年无瘤生存率[(81.9±6.8)%]略低于术后无辅助治疗组,但两组比较,差异无统计学意义(P>0.05);术后放疗+化疗组5年总生存率[(87.9±6.0)%]、5年无瘤生存率[(78.3±8.7)%]与术后化疗组、放疗组和无辅助治疗组比较,差异均无统计学意义(P>0.05)。结论术后辅助孕激素治疗≥12个月、化疗、放疗+化疗可以在一定程度上改善高危子宫内膜癌患者的预后。     

外阴癌手术方式与其预后的相关因素分析

目的:探讨手术方式对外阴癌预后的影响,并分析与外阴癌预后有关的因素.方法:回顾性分析广西医科大学附属肿瘤医院1985～2007年收治的54例经手术治疗的外阴癌患者临床资料,其中传统外阴广泛切除17例,传统外阴广泛切除+腹股沟淋巴结切除13例;改良外阴广泛切除9例,改良外阴广泛切除+腹股沟淋巴结切除15例.应用SPSS软件对不同的手术方式和有关预后因素进行比较分析.结果:①传统术式与改良术式患者的临床病理特征比较差异无统计学意义(P>0.05).②改良外阴广泛切除的手术时间、术中出血量与传统术式比较差异无统计学意义(P>0.05),但术后外阴切口愈合时间明显缩短(P<0.05).改良外阴广泛切除+腹股沟淋巴结切除的手术时间及术后外阴切口愈合时间较传统术式明显缩短(P<0.01;P<0.05),下肢水肿和麻痛的发生率显著下降(P<0.05),但术中出血量及术后腹股沟切口愈合时间的缩短,差异无统计学意义(P>0.05).③生存分析显示改良术式的5年存活率较传统术式并无明显提高,复发率亦未明显下降(P>0.05).COX模型多因素分析显示手术方式并非影响外阴癌患者预后的因素.结论:改良手术方式可改善外阴癌患者术中、术后情况,但并不影响预后.     

宫颈腺癌86例临床分析

目的探讨宫颈腺癌的临床特点和预后影响因素。方法回顾性分析2000年1月至2009年1月解放军总医院妇产科收治的86例宫颈腺癌患者的临床资料。结果 86例患者5年总生存率为62.3%,其中临床期别Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的5年生存率分别为83.3%、62.5%、13.7%和0。淋巴结转移患者5年生存率为21.4%,无淋巴结转移患者5年生存率85.1%,两者比较,差异有统计学意义(P0.05);血CA125、CA199水平升高均合并淋巴结转移;保留卵巢患者总5年生存率为80.0%,不保留卵巢患者总5年生存率是59.7%,两者比较,差异无统计学意义(P0.05)。结论临床期别、淋巴结转移是影响宫颈腺癌预后的主要因素;早期宫颈腺癌保留卵巢不影响生存率;CA125、CA199的检测对宫颈腺癌预后判断有一定的参考价值。     

同步放化疗与新辅助化疗术前用药在局部中晚期宫颈癌治疗中的临床疗效评价

目的:比较同步放化疗与新辅助化疗术前用药在治疗局部中晚期宫颈癌的临床疗效。方法:选择2002年3月至2005年3月我院收治的42例ⅠB2～ⅡB期宫颈癌患者,其中21例同步放化疗,21例新辅助化疗。两组化疗方案相同,鳞癌:顺铂(DDP)+博来霉素;腺癌:DDP+5-氟尿嘧啶(5-Fu)+丝裂霉素(MMC)。同步放化疗组化疗期间配合放疗,采用腔内近距离放疗。同步放化疗、新辅助化疗结束后选择合适时间手术。观察两组间的近期疗效、手术率及手术切缘阴性情况、毒副反应、远期疗效(1、3、5年生存率)。结果:两组间近期疗效差异无统计学意义(P>0.05)、手术率及手术切缘阴性率差异有高度统计学意义(P<0.01)。血液和胃肠道毒副反应差异无统计学意义(P>0.05),晚期并发症放射性直肠炎和膀胱炎差异有高度统计学意义(P<0.01)。1年、3年生存率差异无统计学意义(P>0.05),而5年生存率同步放化疗组高于新辅助化疗组(P<0.05)。结论:同步放化疗术前用药治疗局部中晚期宫颈癌优于新辅助化疗。     

特殊类型子宫内膜癌的临床特征及预后分析

目的:比较特殊类型子宫内膜癌不同病理类型的临床特征及预后,探讨影响特殊类型子宫内膜癌预后的危险因素及辅助治疗。方法:回顾性分析2009年1月至2017年9月青岛大学附属医院初治的135例特殊类型子宫内膜癌的临床资料,比较分析79例子宫浆液性癌(USC组)、15例透明细胞癌(CCC组)、17例癌肉瘤(CS组)和24例混合细胞腺癌(MCA组)的临床特征及预后。结果:①4组患者在年龄≥60岁、绝经、肿瘤大小、盆腔淋巴结转移及大网膜转移比例方面比较,差异均有统计学意义(P<0.05)。②USC组、CCC组、CS组和MCA组患者的5年总体生存率(OS)分别为63.1%、79.4%、37.6%、87.5%,4组间差异有统计学意义(P<0.05)。I期患者术后行单纯化疗、化疗联合放疗和无治疗组的5年OS分别为94.4%、100.0%、58.1%,不同治疗方式组间差异有统计学意义(P<0.05),前2组患者的预后均明显优于无治疗组(P<0.05)。③经Cox回归多因素分析筛选后,深肌层浸润(HR 1.833,95%CI 1.017～3.306)、分期(HR 1.763,95%C...     

118例ⅡB～ⅣA期宫颈腺癌单纯放疗与同步放化疗生存情况及其预后因素分析

目的:探讨ⅡB~ⅣA期宫颈腺癌患者采用单纯放疗与同步放化疗的生存情况,并分析影响其预后的相关因素,从而探讨ⅡB~ⅣA期宫颈腺癌较理想的治疗方法。方法:回顾性分析1986年1月至2010年12月于我院接受单纯放疗与同步放化疗治疗的ⅡB~ⅣA期宫颈腺癌患者118例的临床资料,对其生存情况及预后相关因素进行分析。结果:本组病例5年总体生存率为47.5%,行单纯放疗与同步放化疗的5年生存率分别为32.7%和59.1%,差异有统计学意义(P0.05)。按分期分层分析:单纯放疗组与同步放化疗组ⅡB期5年生存率分别为48.3%和63.3%,差异无统计学意义(P0.05)。ⅢB期5年生存率分别为22.2%和47.1%,差异有统计学意义(P0.05)。按组织学分级分层分析:单纯放疗组与同步放化疗组5年生存率G1分别为42.9%和61.9%,差异无统计学意义(P0.05);G2分别为33.3%和55.2%,G3分别为18.2%和50.0%,差异均有统计学意义(P0.05)。单因素分析与多因素分析均提示临床分期、组织学分级、肿瘤最大径线及治疗方法是影响ⅡB~ⅣA期宫颈腺癌预后的独立因素(P0.05)。结论:ⅡB~ⅣA期宫颈腺癌单纯放疗与同步放化疗相比,同步放化疗有一定优势,尤其是对ⅢB期及组织学分级G2、G3的患者,能够提高5年生存率。临床分期、组织学分级、肿瘤最大径线及治疗方法是影响ⅡB~ⅣA期宫颈腺癌预后的因素。     

外阴癌39例手术治疗及预后分析

目的 总结我院治疗外阴癌的手术方式,分析与外阴癌预后有关的因素。方法 回顾性分析我院１９７９－１９９７年收治的３９例侵袭性外阴癌的临床资料。其中外阴病灶局部切除术５例、部分外阴根治术１３例及全外阴根治术２１例。应用ＳＰＳＳ地不同的手术方式秀关预后因素进行比较分析。结果 ３９例中鳞癌３３例,占８４．６％,其中高、中、低分化分别为２６、５、２例。临床分期为Ⅰ期７例（１７．９％）Ⅱ期１７例（４３．６％）     

Behandlungsformen und-Ergebnisse beim invasiven Vulvakarzinom

Between 1970 and 1982, 113 patients were treated for invasive vulvar cancer in FIGO stages I-IV; 97 patients were available for follow-up. Forty-one patients (42.3%) underwent radical vulvectomy and lymphadenectomy, 21 underwent simple vulvectomy, and 12 (12.4%) had electric resection of the lesion; 42 patients (43.3%) received postoperative radiotherapy. The 5-year survival rate was 61.8% after surgery and radiotherapy. Five-year survival in stages I, II, and III was 85.3%, 60.7%, and 17.9%, respectively. Overall 5-year survival was 52.6%. Patients with small, highly differentiated squamous cell cancers, without lymph node involvement, did best.     

Management of vulvar melanoma.

Considerable debate centers on the optimal treatment for vulvar melanoma, as well as those clinicopathological factors influencing prognosis. We reviewed 80 patients with vulvar melanoma seen between 1949 and 1990. Primary tumors were assessed according to Chung (47 patients) and Breslow (65 patients) microstaging systems. Fifty-nine patients (76%) underwent radical vulvectomy, ten patients (13%) had a partial vulvectomy, and nine patients (12%) had a wide local excision. Fifty-six also underwent inguinal node dissection. Median follow-up was 193 months. Median survival was 63 months. Ten-year survival by Chung level was as follows: I 100%; II, 81%; III, 87%; IV, 11%; V, 33%. Ten-year survival by tumor thickness was as follows: 0.75 mm, 48%; 0.75-1.5 mm, 68%; 1.51-3.0 mm, 44%; greater than 3.0 mm, 22%. Increased depth of invasion was associated with increased incidence of inguinal node metastasis. Cox regression analysis demonstrated prognostic significance for tumor thickness (P less than 0.001), inguinal node metastasis (P less than 0.001), and older age at diagnosis (P less than 0.001). Radical vulvectomy did not seem to improve survival over less radical procedures. Based on this experience, we recommend radical local excision for patients with malignant melanoma of the vulva. Patients who have more than a superficially invasive melanoma should also have inguinal lymph node dissection.     

Epidermal Growth Factor Receptor in Vulvar Malignancies and Its Relationship to Metastasis and Patient Survival

Objective.To evaluate the level of epidermal growth factor receptor (EGF-R) expression in vulvar malignancies and to determine if a correlation exists between EGF-R levels and metastasis or patient survival.Methods.All patients with a diagnosis of invasive squamous cell carcinoma of the vulva who were treated at our institution with a primary radical vulvectomy and inguinal lymph node dissection from 1983 to 1993 were eligible for the study. Sixty-one patients with available tissue blocks of benign vulvar epithelium, the primary malignant vulvar lesion, and groin node metastasis (when positive) were included in the study. Semiquantitative EGF-R expression was determined in a blinded fashion utilizing immunohistochemical staining of appropriate tissue samples. Survival was calculated utilizing Kaplan–Meier life table analysis based upon disease-free survival.Results.A significant increase (P< 0.001) in mean EGF-R levels was demonstrated in the primary tumor (67%) versus benign vulvar epithelium (31%). In the 14 patients with lymph node metastasis, the mean EGF-R level in the primary tumor was 65% versus 88% in the metastatic lesion (P< 0.001). The likelihood of lymph node metastasis was elevated in those patients with a benign tissue EGF-R level ≥40% (P< 0.03) and in those patients with a primary tumor EGF-R level ≥90% (P< 0.025). Life table analysis revealed a cumulative disease-free survival of 45% for all patients. Disease-free survival in those patients with EGF-R levels ≥90% in the primary tumor was 25%, contrasting with a disease-free survival of 54% in those patients with EGF-R levels <90% (P< 0.05).Conclusions.There is a progressive increase in EGF-R expression from benign vulvar epithelium to primary malignant tissue to metastatic lesions within the same patient. Increased expression of EGF-R in the primary vulvar malignancy is significantly associated with lymph node metastasis and decreased patient survival. Increased expression of EGF-R in histologically benign vulvar epithelium has a significant association with lymph node metastasis and may predict decreased patient survival.     

A matched comparison of single and triple incision techniques for the surgical treatment of carcinoma of the vulva.

Thirty-two patients with invasive squamous cell carcinoma of the vulva (SCC) undergoing radical vulvectomy or radical local excision with bilateral superficial groin node dissection using a triple incision technique (TI) were matched for new FIGO stage, lymph node status, size of lesion, and site of lesion with patients with SCC undergoing traditional radical vulvectomy with en bloc bilateral groin (but not pelvic) node dissection using a single incision (SI) technique. Average operative time (134 min: 191 min), blood loss (424 ml: 733 ml), and hospital stay (9.7 days: 17.2 days) were significantly less in the TI group. After SI 6/32 (19%) patients and after TI 1/32 (3%) patients experienced complete breakdown of the groin wounds. There was no significant difference in overall survival (P = 0.56) or disease-free survival (P = 0.53) between the two groups. There was no significant difference in survival between the two groups by lesion size or by FIGO (1989) stage. Disease recurred in six patients after SI compared with seven after TI (P = 0.75). There were no skin bridge recurrences in the TI group. Two patients in each group had isolated vulvar recurrences and all four were successfully treated by local excision. These data indicate that outcome following TI surgery is essentially equal to that of SI in early-stage disease but major morbidity is much reduced.     

Carcinoma of the vulva. Clinicopathologic factors involved in inguinal and pelvic lymph node metastasis

Eighty-five women with vulvar squamous cell carcinoma were subjected to radical vulvectomy with bilateral inguinal and femoral node dissection or to radical vulvectomy with bilateral inguinofemoral and deep pelvic node dissection. The association between lymph node status (metastatic or not) and several parameters was analyzed: tumor location, size and clinical stage; tumor thickness, histologic grade and mitotic index; blood vessel, lymphatic and perineural infiltration; and lymphocytic and plasma cell infiltrates. There were no metastases to the pelvic lymph nodes without previous inguinal lymph node involvement. Unilateral vulvar carcinomas did not have contralateral metastatic nodes when there was no ipsilateral nodal involvement. Lymphatic vessel infiltration showed a statistically significant correlation with inguinal node metastases (P less than .05). No correlation was found between lymph node metastasis and tumor size, clitoral invasion, tumor thickness, histologic grade, blood vessel and perineural infiltration, lymphocytic and plasma cell infiltrates, and mitotic index.     

Comparison of clinical versus surgical staging systems in vulvar cancer.

OBJECTIVE: To compare prognostic information from the new surgical staging system of the International Federation of Gynecology and Obstetrics (FIGO) with the old clinical staging system for vulvar cancer. METHODS: One hundred six women with previously untreated squamous cell carcinoma of the vulva who underwent radical vulvectomies and inguinal lymph node dissections at the University of Oklahoma from 1971-1990 were considered eligible for this study. A retrospective chart review was conducted to assign surgical stage. The clinical and pathologic factors analyzed for survival included the clinical and surgical stage of disease, nodal status, tumor size, and lesion location. RESULTS: Overall 5-year survival was 64%. Forty-three patients had inguinal and femoral node metastasis with a 5-year survival of 38%, versus 87% for patients without nodal metastasis (P < .00001). An increased number of positive groin lymph nodes was associated with a poorer prognosis. Thirty-one patients had tumors of 2 cm or less in maximum diameter with no recurrences, versus 52% 5-year survival in the remaining patients (P < .001). Perineal involvement was identified in 24 patients, but did not significantly influence survival. CONCLUSION: Overall, the new classification system revised by FIGO for vulvar cancer staging places patients into more accurate risk categories.     

Prognostic variables in the treatment of squamous cell carcinoma of the vulva

Records of 98 patients undergoing surgery for squamous cell carcinoma of the vulva between 1960 and 1982 were analyzed to evaluate and develop treatment policy. There were 32, 34, 26, and 6 patients in FIGO stages I-IV, respectively. Eighty-six patients underwent radical vulvectomy, 8 patients underwent less extensive procedures, and 4 underwent more extensive procedures. Eighty-seven patients underwent inguinal node dissection, and 40 underwent pelvic node dissection as well. Eight patients received external beam irradiation. Actuarial 5-year survival was 57%. Age, tumor size, FIGO (clinical) stage, surgically determined T and N stages, tumor differentiation, lymph vessel invasion, extent of surgical procedure, and adjuvant irradiation were analyzed to determine their effects on local control, freedom from distant metastases, and survival, using single variable and multivariate analysis. Local control was significantly related to FIGO stage; freedom from distant metastasis was significantly related to surgical N stage, tumor size, and surgical T stage; survival was significantly related to surgical N stage, tumor size, surgical T stage, age, and lymph vessel invasion. Metastatic involvement of inguinal lymph nodes was significantly correlated with tumor size and differentiation. Of 87 evaluable patients, 33 had inguinal node involvement, and of these, 17 developed recurrent disease. All 7 patients with pelvic node metastases had positive inguinal nodes, and all died; the cause of death could be determined in 5, of whom 4 manifested distant metastases. Pelvic lymphadenectomy conferred no survival benefit in this series, even in the presence of positive inguinal nodes. Local vulvar recurrence is a significant problem in patients with positive inguinal nodes, and postoperative irradiation should be directed to this area in these patients. Patients with vulvar recurrences, especially those occurring at least 2 years after surgery, can be successfully salvaged, and should therefore be treated aggressively.     

Advanced primary carcinoma of the Bartholin gland: report of 18 patients

Conservative surgery plus radiotherapy for vulvar cancer has been established as a therapeutic alternative to extensive radical surgery and produces a similar cumulative 5-year survival. We retrospectively analyzed the cases of 18 patients with advanced primary carcinoma of the Bartholin gland treated with wide local excision (WLE) or radical vulvectomy and lymphadenectomy followed by radiotherapy (RT) at the University of Texas M. D. Anderson Cancer Center from January 1978 through December 1990. All patients have been observed for a minimum of 7 months (maximum follow-up, 15 years; median follow-up, 9 years). Of the 18 patients, 7 were treated with wide local excision (WLE) followed by radiation therapy (RT) (Group 1), 9 had radical vulvectomy (RV) followed by RT to the vulvar and inguinal-femoral and pelvic node areas (Group II), and 2 were treated with RT alone after biopsy of the tumor (Group III). The 5-year disease-free survival rates were 86%, 78%, and 50% for groups I, II, and III, respectively, and 83% for the whole group. Of 2 patients treated with RT alone, one lived for 6 years with no evidence of disease, and the other lived for 20 months. The rate of local tumor control was 100% for all three treatment groups. There were no significant differences among the treatment groups in rate of primary tumor control or 5-year disease-free survival rate (p=0.1300). The present study demonstrated WLE followed by RT is the best treatment for advanced primary carcinoma of the Bartholin gland. Less radical surgery plus RT produces good long-term survival and has fewer complications.     

SEER Data, Corpus Uteri Cancer: Treatment Trends versus Survival for FIGO Stage II, 1988–1994

OBJECTIVE: 1998 Surveillance, Epidemiology, and End Results (SEER) data estimate an 83.1% 5-year survival rate for corpus uteri adenocarcinoma FIGO stage II. The SEER data were evaluated to determine whether primary treatment differences using simple hysterectomy or radical hysterectomy, with or without radiation, altered disease survival. MATERIALS AND METHODS: SEER incidence data for FIGO II uterine corpus cancer of adenocarcinoma histology from 1988 to 1994 were stratified by hysterectomy type (simple versus radical) and whether radiation was given. Survival rates were calculated using a relative survival method and are expressed as percentages. Statistical analysis was done using a Z test. RESULTS: The 5-year cumulative survival rate for patients with stage II uterine corpus adenocarcinoma who received surgery alone as primary therapy was 84.36% with simple hysterectomy and 92.96% with radical hysterectomy (P<0.05). Survival for patients who received combination radiation and surgery as primary therapy was 82.77% with simple hysterectomy and 88.02% with radical hysterectomy (P<0.05). Pelvic and para-aortic nodes were negative. There was no significant survival difference for radiation versus no radiation in either surgical group. CONCLUSION: Radical hysterectomy is associated with better survival when compared to simple hysterectomy for FIGO II corpus uteri adenocarcinoma.